Benzinga · Aug 11, 2026
HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
HR
NASDAQ · HRTX
Heron Therapeutics, Inc.
Healthcare · Biotechnology
$0.31
Up+$0.01 (+2.98%)
Updated Aug 21, 2026, 11:21 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 214.8M
- P/E ratio
- -224.99
- Dividend yield
- 0.00%
- 52-week range
- $0.30 – $1.34
- Volume
- 1.98M
- Avg. volume
- 1.85M
Price performance
HRTX price history
1M range · 0 trading sessions · Daily adjusted prices
HRTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest HRTX news
The latest Smart Investors Daily articles mentioning HRTX.
Stock researchCompany · Overview
HRTX research
Overview
Company profile and research snapshot.
Company profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2026 | Needham | Hold | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 8, 2025 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 10, 2026
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call August 10, 2026 8:30 AM EDTCompany ParticipantsMelissa Jarel - Vice President of LegalCraig Collard -...
Benzinga · Aug 10, 2026
Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share
SeekingAlpha · Jun 10, 2026
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Heron Therapeutics hit as court invalidates key Cinvanti patents; Zynrelef canât offset losses.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
